fda compounded semaglutide enforcement news The is drawing a harder line on weight loss drug marketing. In the May–June 2026 issue of Dispense Times, this article breaks down key violations cited in recent FDA Compound versions of GLP-1 drugs

Combining BPC-157, NAD+, and GHK-CU, this formulation focuses on pathways associated with tissue repair, cellular energy production, and healthy skin and connective tissue support

However, GLP-1 receptors are also present in skeletal muscle tissue, where the medication can influence cellular ion balance and electrolyte handling

Great product and company

With PA approved on Tier 3, expect a copay of $40 to $100 per month for commercial plans, depending on benefit design

Among those subscribers, nearly 1.5 million collaborated with a provider to receive a personalized treatment, up 89% year over year, co-founder and CEO Andrew Dudum told investors on the company's second-quarter earnings call